Literature DB >> 2040761

Familial prevalence and coaggregation of schizotypy indicators: a multitrait family study.

W M Grove1, B S Lebow, B A Clementz, A Cerri, C Medus, W G Iacono.   

Abstract

Schizophrenic probands (n = 17), their first-degree relatives (n = 61), and medically and psychiatrically screened normal control subjects (n = 18) were studied with structured interviews for DSM-III Axis I disorders and schizotypal personality disorder, questionnaire measures of schizotypy, measures of smooth-pursuit eye movement dysfunction, and attention dysfunction. Schizophrenic subjects scored abnormally on essentially all measures. Relatives differed significantly from control subjects on most measures. Correlational analyses indicate that many characteristics tested in these measures run together in families. The data are consistent with the hypothesis that a single vulnerability dimension or typology, presumably in part genetically transmitted, may account for phenotypically distinct abnormalities. These traits, taken together, may have joint usefulness for identifying persons with a predisposition to schizophrenia.

Entities:  

Mesh:

Year:  1991        PMID: 2040761     DOI: 10.1037//0021-843x.100.2.115

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  23 in total

Review 1.  Schizotaxia: current status and future directions.

Authors:  Ming T Tsuang; William S Stone; Franziska Gamma; Stephen V Faraone
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes.

Authors:  Beth E Snitz; Angus W Macdonald; Cameron S Carter
Journal:  Schizophr Bull       Date:  2005-09-15       Impact factor: 9.306

Review 3.  A multivariate perspective on schizotypy and familial association with schizophrenia: a review.

Authors:  Sarah I Tarbox; Michael F Pogue-Geile
Journal:  Clin Psychol Rev       Date:  2011-07-23

Review 4.  The assessment of schizotypy and its clinical relevance.

Authors:  Oliver J Mason
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

5.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

6.  Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  Keith H Nuechterlein; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

Review 7.  Affective traits in schizophrenia and schizotypy.

Authors:  William P Horan; Jack J Blanchard; Lee Anna Clark; Michael F Green
Journal:  Schizophr Bull       Date:  2008-07-29       Impact factor: 9.306

8.  SPEM dysfunction and general schizotypy as measured by the SSQ: a controlled study.

Authors:  Dirk van Kampen; Jan Berend Deijen
Journal:  BMC Neurol       Date:  2009-06-29       Impact factor: 2.474

9.  Subjective experience of cognitive failures as possible risk factor for negative symptoms of psychosis in the general population.

Authors:  Stefanie Pfeifer; Jim van Os; Manon Hanssen; Philippe Delespaul; Lydia Krabbendam
Journal:  Schizophr Bull       Date:  2008-02-21       Impact factor: 9.306

10.  Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.

Authors:  Monica E Calkins; William G Iacono; Deniz S Ones
Journal:  Brain Cogn       Date:  2008-10-18       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.